Article Text

Download PDFPDF
Defining chronic inflammatory demyelinating polyradiculoneuropathy subtypes
  1. Richard A C Hughes
  1. Department of Neuromuscular Diseases, University College London, London WC1N 3BG, UK
  1. Correspondence to Professor Richard A C Hughes, Department of Neuromuscular Diseases, University College London, London WC1N 3BG, UK; rhughes11{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

An electrophysiological and biopsy study of 106 patients with chronic inflammatory demyelinating polyradiculoneuropathy identifies differences between disease subtypes

Chronic inflammatory neuropathies include multifocal motor neuropathy, which is purely motor and often associated with complement-fixing antibodies to ganglioside GM1, paraproteinaemic demyelinating neuropathy associated with IgM paraprotein and antibodies to myelin-associated glycoprotein, and a heterogeneous group of conditions collected under the umbrella term chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Understanding the cause and improving the treatment of CIDP requires refining its subtypes into homogeneous entities.1

The paper by Ikeda et al is a further step in this direction.2 They classified 106 patients with CIDP, all of whom had sural nerve biopsies, into subtypes and reported their electrophysiological and pathological characteristics. In typical CIDP, nerve conduction was especially slowed in proximal and distal nerve segments, while in multifocal acquired demyelinating sensory and motor neuropathy (MADSAM) these portions were spared. The relatively minor average …

View Full Text


  • Contributors RACH conceived and wrote this article at the request of the editor.

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles